Clinical trials: Pancreatic Metastatic Cancer
Cancer, Pancreas
Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients
Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated.
- Trial name
- Oncothermia (NCT02862015)
- Testing
- Oncothermia, FOLFIRINOX or Gemcitabine based chemotherapy
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Pancreas Cancer, Metastatic Pancreatic Cancer
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
- Trial name
- NCT04605913
- Testing
- Modified GCN+TTF treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
This trial is to determine the safest dose of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and rintatolimod that can be given with a DC vaccine as treatment of peritoneal surface…
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Trial name
- NCT02151448
- Testing
- DC vaccine, Celecoxib, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- David Bartlett
Solid Tumor, Hodgkin's Lymphoma
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
This is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.
- Conditions
- Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer
- Trial name
- NCT01929941
- Testing
- INCB047986, Gemcitabine, nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
The goal of this clinical research study is to learn if the study drug SOM 230 in addition to standard therapy of gemcitabine can shrink or slow the growth of pancreatic cancer.
- Trial name
- NCT01385956
- Testing
- SOM 230 LAR, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
Safety study to determine highest dose of 90Y-hPAM4 can be safety administered
- Trial name
- NCT00597129
- Testing
- 90Y-hPAM4
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Pancreatic Cancer
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
The purpose of this study is to find out which doses of talimogene laherparepvec (T-Vec) can be given safely to participants with pancreatic cancer that is either too big to be taken out by surgery or has spread to other parts of…
- Trial name
- NCT03086642
- Testing
- Talimogene laherparepvec
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Karie D. Runcie, MD
Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Colorectal Carcinoma (mCRC)
OSCAR II STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC…
- Trial name
- NCT06655142
- Testing
- ONCObind (Onco-Seraph) 100 Filter, Matched Controls
- Volunteers
- 120 people
- Sponsor
- ExThera Medical Corporation
Neuroendocrine Carcinoma
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine…
- Trial name
- 68Ga (NCT01396382)
- Testing
- 68Ga-DOTATATE PET scan
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
Pancreatic Cancer, Nab-paclitaxel
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
A randomized multi-center phase II trial of nab-paclitaxel in combination with gemcitabine verus S1 with gemcitabine as first-Line treatment for locally advanced or metastatic pancreatic cancer
- Conditions
- Pancreatic Cancer, Nab-paclitaxel, Gemcitabine, S1
- Trial name
- NCT03779464
- Testing
- S1 or Gemcitabine
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic…
- Trial name
- NCT00017199
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastrointestinal Neuroendocrine Tumor
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
The aim of this study is to investigate the efficacy, safety, and survival benefit of etoposide plus cisplatin and irinotecan plus cisplatin in first-line therapy of non-primary pancreatic metastatic and/or unresectable…
- Trial name
- NCT03963193
- Testing
- Etoposide, Irinotecan
- Volunteers
- 112 people
- Sponsor
- Henan Cancer Hospital
Adenocarcinoma, Metastasis
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.
- Conditions
- Adenocarcinoma, Metastasis, Pancreas Neoplasms
- Trial name
- NCT00377936
- Testing
- Gemcitabine alone, EndoTAG-1 and Gemcitabine
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 212 people
- Sponsor
- MediGene
Pancreatic Cancer
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.
- Trial name
- NCT02854072
- Testing
- GV1001, Gemcitabine, Capecitabine
- Where
- 16 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic PDAC patients.
- Trial name
- NCT04523987
- Testing
- Ciprofloxacin
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Neoplasm
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
- Trial name
- NCT00226005
- Testing
- PTK787/ZK222584
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pancreatic Cancer Research Team
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.